Immunomodulatory drugs (IMiDs) have markedly improved patient outcome in multiple myeloma (MM); however, resistance to IMiDs commonly underlies relapse of disease. Here we identify and validate that T
Cells treated with dsRNA targeting Tws, Endos, Gwl or KAN (non-target), or treated with okadaic acid or DMSO were submitted to phosphopeptide enrichment. Products were analyzed by mass spectrometry. R
